NGEN: Nervgen Pharma Corp. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
62 institutions reported holding $24.67M of Nervgen Pharma Corp. on Form 13F (45 the quarter before). 20 opened a new position and 3 sold out. Shares held by institutions: +618%.
| Largest holders | Shares | Value |
|---|---|---|
| Empery Asset Management, LP | 4,000,000 | $8.24M |
| Rock Springs Capital Management LP | 1,208,231 | $2.49M |
| DAFNA Capital Management LLC | 1,050,000 | $2.16M |
| Ghisallo Capital Management LLC | 1,000,000 | $2.06M |
| ARMISTICE CAPITAL, LLC | 678,000 | $1.40M |
| LMR Partners LLP | 600,000 | $1.24M |
| MARSHALL WACE, LLP | 435,962 | $898K |
| UBS Group AG | 379,726 | $782K |
| Stonepine Capital Management, LLC | 271,678 | $560K |
| JANE STREET GROUP, LLC | 270,750 | $558K |
Clinical trial readouts
1 Phase 2 or 3 trials by Nervgen Pharma Corp. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-07 (est.) | NVG-291 | Chronic Spinal Cord Injury | Phase 3 | 150 | Recruiting | NCT07799532 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.